Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. - Wikidata - awgldk - TriplyDB

Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome.

Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome.

http://www.wikidata.org/entity/Q30537599

about

Characterizing autism spectrum disorders by key biochemical pathways.Dysregulation and restoration of translational homeostasis in fragile X syndrome The neurology of mTOR Learning and behavioral deficits associated with the absence of the fragile X mental retardation protein: what a fly and mouse model can teach us.Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back Review of targeted treatments in fragile X syndrome Fragile X mental retardation protein: A paradigm for translational control by RNA-binding proteins Pax6-dependent cortical glutamatergic neuronal differentiation regulates autism-like behavior in prenatally valproic acid-exposed rat offspring In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome From FMRP function to potential therapies for fragile X syndrome.Modeling fragile X syndrome in the Fmr1 knockout mouse A protocol for evaluation of Rett Syndrome symptom improvement by metabolic modulators in Mecp2-mutant mice.A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome.The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments.Spaced training rescues memory and ERK1/2 signaling in fragile X syndrome model mice.Impaired cognitive discrimination and discoordination of coupled theta-gamma oscillations in Fmr1 knockout mice.Data gaps limit the translational potential of preclinical research.β-Arrestin2 Couples Metabotropic Glutamate Receptor 5 to Neuronal Protein Synthesis and Is a Potential Target to Treat Fragile X.Cholesterol in the Pathogenesis of Alzheimer's, Parkinson's Diseases and Autism: Link to Synaptic Dysfunction Delta rhythmicity is a reliable EEG biomarker in Angelman syndrome: a parallel mouse and human analysis.Chd8 Mutation Leads to Autistic-like Behaviors and Impaired Striatal Circuits Fragile X targeted pharmacotherapy: lessons learned and future directions.Dysregulation of group-I metabotropic glutamate (mGlu) receptor mediated signalling in disorders associated with Intellectual Disability and Autism Extinction of an instrumental response: a cognitive behavioral assay in Fmr1 knockout mice.A review of traditional and novel treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel.Identification of fragile X syndrome specific molecular markers in human fibroblasts: a useful model to test the efficacy of therapeutic drugs.Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes.Fragile X mental retardation protein: from autism to neurodegenerative disease.Homer protein-metabotropic glutamate receptor binding regulates endocannabinoid signaling and affects hyperexcitability in a mouse model of fragile X syndrome.Quantitative profiling of brain lipid raft proteome in a mouse model of fragile X syndrome Fmr1 KO and fenobam treatment differentially impact distinct synapse populations of mouse neocortex.Convergence of Hippocampal Pathophysiology in Syngap+/- and Fmr1-/y Mice.Identification of a male with fragile X syndrome through newborn screening Elevated CaMKIIα and Hyperphosphorylation of Homer Mediate Circuit Dysfunction in a Fragile X Syndrome Mouse Model.Layer specific and general requirements for ERK/MAPK signaling in the developing neocortex Targeting Translation Control with p70 S6 Kinase 1 Inhibitors to Reverse Phenotypes in Fragile X Syndrome Mice.Agonist-dependent signaling by group I metabotropic glutamate receptors is regulated by association with lipid domains APP Causes Hyperexcitability in Fragile X Mice.Lipid rafts: a signaling platform linking cholesterol metabolism to synaptic deficits in autism spectrum disorders.

P2860

Q26781645-C7D3BA60-E518-4DBA-898C-3C5BD00E0CA3 Q26782616-A5743931-69B1-48F9-B733-C25730AF66EA Q26824286-72E931AC-ACC0-4C7D-80A6-21199CCF35F9 Q26866506-08AA24A8-E4DA-48BB-9676-2ECA5B197AF3 Q27023257-5B1F1823-EC1B-49BF-BBB9-38E938CDF40F Q27337360-7B5B3BD8-8247-4F5E-9926-1664C33C0E30 Q28077180-F50F8F30-6C22-45CF-9D27-9C9987D5334D Q28086823-5137D06B-3C4C-41DA-96BB-7B39B1E51119 Q28941206-54212CF6-D85C-49E2-BB58-59B4BF11D86B Q30406616-6B90947B-3B2B-4BF6-9239-A9F6D647DFE5 Q30410502-7D900ED7-1DA7-4A2E-AA3C-56A1BB8F1DA0 Q30420595-9C522430-EEAE-432A-B98A-2B0EB8E7758B Q30422702-78D02E57-2F73-4C9E-B57C-D864586E5D37 Q30442429-64350A52-B03F-434C-83CE-E94943B620FB Q30576758-D13CBC18-6362-4644-BE50-13BB5C805B3C Q30603928-E7285288-5C0D-4C2E-81DF-56B63EAE17C5 Q30713841-945968A0-DFC5-4535-8EDD-258444768AF9 Q31035567-16DD4012-C1ED-4301-A093-6BC9D824DE8C Q33562835-AC1D677C-59D1-435C-BF68-0120E0DC9061 Q33607803-0164228E-A3B5-47C2-B9C8-7ABF6BBA28A2 Q33651529-45FC346B-24EC-4DA3-8836-953DFAFDC4BB Q33756508-A33A0AD6-DD0F-4BF8-AA8C-77E4127C0E58 Q33785983-E5E79C57-E72C-45DE-90D6-C4E133B85A31 Q33877423-6D387E1B-78F8-4C37-8C35-C99B5F67EBE7 Q34276734-D0C79B3E-9A5D-4F2A-A580-636571921902 Q34392818-2DC5B28B-1BC8-4B57-A7B6-0CF24BBE5160 Q34871401-743AA7FA-F92D-40E9-9E75-38DC44FDC205 Q34959355-917F4793-7D88-409D-BCC9-42E8FE6AB572 Q35077291-463B15B5-3533-49CD-97B9-72FDCBA90D6C Q35142914-873D3311-253B-4F6B-864C-B096A01FAEFC Q35302189-A713873C-3F25-41BD-BB7A-78091E6EE414 Q35776690-D53CCCD5-F595-45D2-92AD-95B3A2F7B977 Q36272528-D7F9D20B-839F-4703-9955-BD2DCF35EF1F Q36322068-DB7DBDD0-B5AA-40E5-A872-AA13465D8188 Q36387172-9655E5DA-58F6-4158-AE9C-8FB73065C853 Q36594223-FE2AC0D3-E3E2-4638-B70D-BDDA81505FF1 Q37006293-A77D2D9A-BFC0-4FF8-85B7-B58F94081620 Q37272208-FA9B939C-2520-4F0A-BCA0-EF9F30B01F3A Q37504141-8D5209AE-95E8-41D1-A806-36696C7CF3DC Q37681389-10DDB898-3117-4BC4-A084-3292817F1CF5

P2860

Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome.

http://www.wikidata.org/entity/Q30537599

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Lovastatin corrects excess pro ...... e model of fragile X syndrome.

@ast

Lovastatin corrects excess pro ...... e model of fragile X syndrome.

@en

type

label

Lovastatin corrects excess pro ...... e model of fragile X syndrome.

@ast

Lovastatin corrects excess pro ...... e model of fragile X syndrome.

@en

prefLabel

Lovastatin corrects excess pro ...... e model of fragile X syndrome.

@ast

Lovastatin corrects excess pro ...... e model of fragile X syndrome.

@en

P1433

Q30537599-4D2B7583-20E9-4B95-B788-D5FB8524B021

P1476

Q30537599-2B734512-92E4-449A-9A64-0DBD7D658FC6

P2093

Q30537599-6D53E46B-191F-4EB8-999E-8E83A2AEE44F

Q30537599-8A3B4A8B-C195-4043-A401-530EAEEB78E7

Q30537599-D7D15C4B-AE90-4203-A2A9-3AB0159BA81F

Q30537599-E92FFD4F-C6BA-4691-BD2E-884785FACE77

P2860

Q30537599-012373FB-9D2E-41AA-B214-382416A502D3

Q30537599-0E6EF6BD-020C-4E29-93C4-807871F2EEBD

Q30537599-0E7DEFA2-11B9-4CA3-9927-123628A414BB

Q30537599-104B550C-3D01-4EF2-B02C-D22C1716C0CF

Q30537599-16822514-2657-4C18-9C9B-E85B14B24D84

Q30537599-183256B8-8754-441E-834D-BF99CAED9DFC

Q30537599-212A2EDB-5701-440B-A403-CB309063C22A

Q30537599-28452488-B4AE-4627-9BE2-E155DEE36119

Q30537599-288B4E07-550F-439D-8E18-C6FC77C04B50

Q30537599-2D8C678E-6DEF-4F98-8370-1FA020F8BDB3

P304

Q30537599-88659BD7-A65B-4745-9903-EF78EBC77C2D

P31

Q30537599-E9D356E4-CAEB-4FF2-851A-99418E1EBFEF

P356

Q30537599-9AE1A524-8028-424F-AC76-4217F050EF70

P407

Q30537599-63AF02BF-2474-43DA-BED8-AB34EF15568A

P433

Q30537599-A84C89C5-C183-4CB3-B717-D9CA35F8944F

P478

Q30537599-1B7D7EAC-DB7C-49A5-8477-E7BC8D60CC3C

P50

Q30537599-5EF314E8-E02C-45CD-9D22-A0B35592CA6D

Q30537599-B4002FD1-32ED-4E04-BCE4-123209B773F7

Q30537599-BEA61B8C-A1EC-4FB5-A6FB-92325049D066

P577

Q30537599-BCB40290-CCD7-446F-A946-B4877002184B

P5875

Q30537599-0374C224-D0F0-45E4-A0F7-3BECDE29DEAD

P698

Q30537599-21EF1F4E-E91A-436F-8FC1-4B5035E77229

P932

Q30537599-9CF24BAC-B3E0-4647-9349-8741E46B8391

P356

J.NEURON.2012.01.034

P1433

P1476

Lovastatin corrects excess pro ...... e model of fragile X syndrome.

@en

P2093

Mark F Bear

http://www.w3.org/2001/XMLSchema#string

Michael Sidorov

http://www.w3.org/2001/XMLSchema#string

Robert K S Wong

http://www.w3.org/2001/XMLSchema#string

Shih-Chieh Chuang

http://www.w3.org/2001/XMLSchema#string

P2860

The Autistic Neuron: Troubled Translation?

Altered synaptic plasticity in a mouse model of fragile X mental retardation

The pathophysiology of fragile X (and what it teaches us about synapses)

The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1

Regulation of the mevalonate pathway

The mGluR theory of fragile X mental retardation

Cellular plasticity for group I mGluR-mediated epileptogenesis.

Visual experience and deprivation bidirectionally modify the composition and function of NMDA receptors in visual cortex.

Administration of simvastatin after kainic acid-induced status epilepticus restrains chronic temporal lobe epilepsy.

Concepts in Ras-directed therapy.

P304

243-250

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NEURON.2012.01.034

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

77

http://www.w3.org/2001/XMLSchema#string

P50

Emily Osterweil

Riccardo Bianchi

Alexander A Chubykin

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235374285

http://www.w3.org/2001/XMLSchema#string

P698

23352161

http://www.w3.org/2001/XMLSchema#string

P932

3597444

http://www.w3.org/2001/XMLSchema#string